[ Inside the business ]

ANIP stock analysis

ANIP · Ani Pharmaceuticals Inc

Pharmaceutical preparations. Growing 28%.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#9 of 20 mentioning it
03 Will customers keep buying?Customer Four: 22% of sales
Customer Four 22%Customer One 17%Customer Three 14%Customer Two 9%Everyone else
Prepaid $5MSales +28%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 55% → 58%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +8.0%/yrDebt $298M
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +20%, +26%, then +28% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 0.8× the market. In the 2008 crisis it fell 77% while the market fell 51%. Debt is covered by cash.

Speculative check

Not classified.

Not Self-funding because of: issuing 5%+ new shares a year.

What they sell

48% Sales of Cortrophin Gel.

Sales of Cortrophin Gel 48% · Sales of Generic Pharmaceutical Products 36% · Sales of ILUVIEN and YUTIQ 8% · Sales of Established Brand Royalties and Other Revenues 4% · other (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Early maturity.

It earns cash, still invests, and pays back more than it borrows. Unusually, sales are still growing like a young company's.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 196¢ of each $1 of profit.

Competitive advantage

2 of 10 years.

Returns beat its 8.0% cost of capital in 2 of the last 10 years. Gross margin went from 62% to 58%.

Future bets

5% on research.

$51M a year on R&D. $24M on equipment and buildings.

All figures from Ani Pharmaceuticals Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.